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ABSTRACT
We have isolated the human protein SNEV as down-
regulated in replicatively senescent cells. Sequence
homology to the yeast splicing factor Prp19 sug-
gested that SNEV might be the orthologue of Prp19
and therefore might also be involved in pre-mRNA
splicing.Wehaveusedvariousapproachesincluding
gene complementation studies in yeast using a tem-
perature sensitive mutant with a pleiotropic pheno-
type and SNEV immunodepletion from human HeLa
nuclear extracts to determine its function. A human–
yeast chimera was indeed capable of restoring the
wild-type phenotype of the yeast mutant strain. In
addition, immunodepletion of SNEV from human
nuclear extracts resulted in a decrease of in vitro
pre-mRNA splicing efficiency. Furthermore, as part
of our analysis of protein–protein interactions within
the CDC5L complex, we found that SNEV interacts
with itself. The self-interaction domain was mapped
to amino acids 56–74 in the protein’s sequence and
synthetic peptides derived from this region inhibit
in vitro splicing by surprisingly interfering with
spliceosome formation and stability. These results
indicate that SNEV is the human orthologue of
yeast PRP19, functions in splicing and that homo-
oligomerization of SNEV in HeLa nuclear extract is
essential for spliceosome assembly and that it
might also be important for spliceosome stability.
INTRODUCTION
In our search for novel factors involved in the control of
cellular life span in vitro we previously screened for genes
that are differentially expressed in senescent versus early pas-
sage human umbilical vein endothelial cells (HUVECs) (1).
From the identiﬁed genes we selected one, unknown gene 4, in
order to test if it inﬂuences the replicative life span of
HUVECs when overexpressed. Indeed, we observed that the
transfected cells underwent more population doublings than
the cells transfected with a control vector (2). Therefore, we
termed the corresponding protein senescence evasion factor
(SNEV). Sequence analysis of SNEV showed similarity to
the Saccharomyces cerevisiae protein Prp19p/Pso4p/Xs9
(Figure 1), which has been identiﬁed independently by two
different approaches: On the one hand it has been character-
ized as yeast Prp19p, a protein that is essential for splicing
(3,4) and a subunit of the highly conserved nineteen complex
(NTC), a complex consisting of several spliceosomal
proteins (5–9).
On the other hand, studies within the ﬁeld of DNA repair
have identiﬁed it as Pso4p by complementation of the yeast
strain pso4-1, a psoralen sensitive mutant (10). The phenotype
of this yeast mutant strain is pleiotropic and comprises
temperature sensitivity, mutagen and radiation sensitivity, a
block of sporulation, impaired induced mutagenesis (11–13)
aswellasaccumulationofpre-mRNA (14).Thesestudieshave
provided a novel link between pre-mRNA processing and
DNA repair (10,15) and suggest that Prp19p is involved in
at least these two different and highly interesting cellular
processes.
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doi:10.1093/nar/gki986Human SNEV, however, has been identiﬁed simultaneously
to our studies as human nuclear matrix protein hNMP200 (16).
Since it displays E3 ubiquitin ligase activity in vitro (17), it is
highly probable that it is involved in the ubiquitin proteasome
system in vivo. In line with this ﬁnding, we reported recently
that it associates directly with the 20S proteasome, suggesting
that it escorts its ubiquitinated (but still unknown) substrate(s)
to the site of destruction (18).
In addition to these reports, SNEV has been found to be
contained within the CDC5L complex by independent studies
(19–21), a subspliceosomal complex containing highly similar
proteins as the NTC complex in yeast.
During pre-mRNA splicing the non-coding intronic
sequences of the nascent RNA transcripts of RNA polymerase
II are removed and the coding exons are joined together to
form mature mRNA within the cell nucleus. This mRNA is
then exported for translation into the cytoplasm. The large
complex that is responsible for this catalysis, the spliceosome,
consists of many RNA and protein factors that assemble in a
stepwise manner around the pre-mRNA before catalysis (22).
Besides the RNA components that form four ribonucleopro-
tein (snRNP) particles (U1, U2, U5 and U4/6.U5), multiple
non-snRNP associated proteins that are essential for
spliceosome assembly and activity (23). One subcomplex
that seems highly conserved from yeast to human is the
NTC (in yeast), or Prp19/CDC5L associated complex in
human cells. The human complex is essential for the pre-
mRNA splicing catalysis and consists of the core proteins
CDC5L, SNEV/Prp19, Hsp73, PLRG1 and SPF27 (19,21).
Dependent on the author of the experiments either AD002
and b-catenin-like 1 are found as members of the core
complex (19,21) or CCAP6 (19). However, this complex is
stably associated with the activated spliceosome as well as
with a novel 35S form of the U5 snRNP (21), and depletion
of this complex leads to block of the splicing reaction
before the ﬁrst catalytic step, during which the lariat is
formed (21). Similarly, in yeast NTC is required for splicing
catalysis (3), stable association of U5 and U6 with the
spliceosome after U4 is dissociated and for a structural
change in U6 snRNP (24). Furthermore, the NTC has
recently been reported to be implicated in regulating the
ﬁdelity of splice site selection (25). Recruitment of the
NTC to intron containing genes during transcription also
supports the hypothesis that pre-mRNA splicing occurs
co-transcriptionally (26).
Although SNEV has been found within the CDC5L/Prp19
complex, a direct role of SNEV in the human pre-mRNA
splicing process has not been addressed so far and therefore
A
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Figure1.SequencecomparisonofSNEVandPrp19p.(A)DomainarchitectureofhumanSNEVandyeastPrp19pissimilarandconsistsofaUFD2likebox(U-box),
alowcomplexityregion(LCR),acoiledcoilregion(CC),aputativeglobulardomain(?),aswellasachargedregion(+++).(B)AlignmentbyBLASTshows23%
overall identities (423/504; 23% identities and 42% positives). Highest homology can be seen at the N-terminus, whereas the C-terminus differs.
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of Prp19p.
In this study we have addressed these questions by comple-
mentation studies in the pso4-1 yeast mutant strain. Indeed, a
human–yeast chimeric protein is able to restore the yeast wild-
type phenotype. Additionally, we show that SNEV presence is
required in human nuclear extracts for in vitro pre-mRNA
splicing. Furthermore, we observed that formation of SNEV
homo-oligomers is essential for the assembly of the spliceo-
some at a surprisingly early step. These results strongly sug-
gest that SNEV is the orthologue of Prp19p and underline its
multifaceted nature that seems to connect as distinct cellular
functions as mRNA processing, protein degradation, DNA
repair and replicative senescence.
MATERIALS AND METHODS
Protein sequence analysis
The protein sequences have been tested for the occurrence of
low complexity regions with the SEG program (27) coiled coil
segments (28), transmembrane regions (29), sequence com-
positional properties (30) and the occurrence of described
globular domains from the PFAM (31) and SMART (32)
databases. The existence of typical short structural repeats
was also tested with the REP tool (33). The remaining
suspected globular protein segments have been subjected to
iterative databases with the BLAST/PSI-BLAST tool (34).
Construction of plasmids and transformation into yeast
PCR, transformation of Escherichia coli cells, restriction reac-
tions, DNA ligations and other recombinant DNA techniques
wereperformed following standard protocols(35).Inbrief, the
open reading frames (ORF) of Prp19 and SNEV were cloned
into the yeast expression vector pYPGE15 under the control of
the constitutive PGK promoter. For cloning of the chimeric
proteins, the human and yeast gene parts were ampliﬁed by
PCR and fused to a His6-tag using primers carrying an asym-
metric BpmI restriction site, that allowed seamless transition
of human to yeast sequence (Table 1). The constructs were
introduced intothe yeast strain MG5128 (MATa/MATa,ura3-
52/ura3, can1/CAN, pso4-1/pso4-1) by LiAc transformation
(36). Yeast clones were selected on media lacking uracil.
Furthermore, SNEV and truncated SNEV cDNAs were lig-
ated into pGADT7 and pGBKT7 for yeast two hybrid analysis,
into pEYFP-C1, pEYFP-N1, pECFP-C1 and pECFP-N1 for
Fluorescence resonance energy transfer (FRET) analysis,
(Clontech Laboratories, Palo Alto, USA) as well as into
pGEX-6P-1 (Amersham Biosciences, Uppsala, Sweden) for
glutathione S-transferase (GST)-fusion protein expression.
Table 1. Primers used in this study
Primer name Sequence
Prp19 start sense AattagcaattggccaccATGCTTTGTGCTATTAGTGG
Prp19 stop as GacgctcgagaacTTAGGGTGTCAATGCAACAATA
Prp19 stop as 6His GacgctcgagaacctaatgatgatgatgatgatgGGGTGTCAATGCAACAATATTG
SNEV start sense AattagcaattggccaccATGTCCCTAATCTGCTCCAT
SNEV stop as 6His gacgctcgagaacctaatgatgatgatgatgatgCAGGCTGTAGAACTTGAGGC
SNEV fastbac sense gacggaattcCTCGGTCCGAAACCATGTCG
SNEV stop as gacgctcgagaacCTACAGGCTGTAGAACTTGAG
SNEV Ubox as BpmI ctttcactggagCCGGGATGCTGGTGGCTG
Prp19 wo Ubox sense BpmI atcagctggagAGTCTACAAACTCTGCTACG
Prp19 wo Ubox sense ATG AattagcaattggccaccatgGCTACGTTAAAAGCGAATTATTC
SNEV 273 as BpmI atcatgctggagCGGGTTGTCTGCAGtgaGCGCAGAGTGA
Prp19 289 sense BpmI aattagctggagCTTTAAGTTACGATCAACTCTAGATAG
Prp19 289 sense ATG aattagcaattggccaccatgTTACGATCAACTCTAGATAG
Prp19 291 as BpmI atcatgctggagCTATCTAGAGTTGATCGTAAC
SNEV 264 sense BpmI aattagctggagCAGCTTCACTCTGCGACAGCAGCT
Prp19 297 stop as gacgctcgagaacctaatgatgatgatgatgatgTCGTAACTTAAAGTTTTCGAGC
SNEV 630 as BpmI atcatgctggagCACCTGCCGGTATTTGCTG
Prp19 607 sense BpmI AattagctggagTCTATGTACTATGAcAAATGGGTG
Prp19 622 sense ATG aattagcaattggccaccatgAAATGGGTGTGCATGTGTCG
SNEV 1470 as BpmI atcatgctggagTCTTAAGCTTGCGCAGATCCC
Prp19 1187 sense BpmI aattagctggagTGGTTTGCTTTGACCTAAGAAAG
Prp19 1198 sense ATG AattagcaattggccaccatgGACCTAAGAAAGGATGTCGGC
PGK Promoter sense CAAGATCTCGACTCTAGAGG
Cyc1 Terminator as GCCTGTTTACTCACAGGC
SNEV 8 as new AAGACTGTGCCTGAGGAGCTG
Prp19 503 sense AGCTCAAAGCACCCAAATGG
SNEV sense GTAGAATTCATGTCCCTAATCTGCTCCATC
SNEV antisense ATACAAGTCGACCTACTGAGATGAGGCCCAGC
SNEV (DU90) sense GTAGAATTCACTCTGCGCCAGCAGCTG
SNEV 56 sense GTAGAATTCAAAGTTGCTCACCCAATCCG
SNEV 66 sense GTAGAATTCCCCTCAGCCACCAGCATCCC
SNEV 76 sense GTAGAATTCAAAGCTTTGCAGGATGAGTG
SNEV 92 antisense ATACAAGTCGACGTCTGCAGCTGCTGGCGCAG
SNEV 103 antisense ATACAAGTCGACTGGTACAGAGCGTGTGAC AG
SNEV 121 antisense ATACAAGTCGACGCAGCAGTGACTTCCTTGGT
Capitallettersrepresentnucleotidescomplementarytothetemplate,underlinedlettersspecifyrestrictionsites,Kozakconsensussequencesareinitalicandadditional
initiation- and termination triplets are in bold letters.
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tion into yeast or transfection into HeLa cells. The expression
plasmid containing SNEV for expression in the insect cell/
baculovirus system was kindly provided by Prof. Hatakeyama.
Growth, sporulation and forward mutability
Transformed yeast clones were tested for growth at 30 and
37ConSDagar plates,fortheir ability tosporulateat30Con
KAC agar plates and for mutability on Canavanine containing
media as described (10).
Antibody production and affinity purification
Synthetic peptides were designed from the protein sequence of
SNEV, synthesized and antibodies raised against them were
puriﬁed commercially (Eurogentec, Belgium). Peptide
sequences used for antibody production were as follows:
SNEV-865: 33-YIAENGTDPINNQPL-S-48, SNEV-866:
185-TERKKRGKTVPEELV-C-199; SNEV-867: 336-QTG-
RVLT KVTDETSG-C-350. The antisera were afﬁnity puriﬁed
against the peptides used to raise the antibodies (Eurogentec).
Afﬁnity puriﬁed antibodies were dialyzed against phosphate-
buffered saline (PBS) containing 0.02% sodium azide and
stored at 80C.
Monoclonal antibodies to SNEV were produced using a
novel FACSbased techniqueandafter recombinantexpression
puriﬁed from culture supernatants using Protein A agarose
beads (37).
SDS–PAGE and western blotting
SDS–PAGE gel analysis was done as described previously
(38). For protein expression analysis of the transformed
MG5128 yeast strain, lysis was performed using 1 ml breaking
buffer [50 mM sodium phosphate (pH 7.4), 1 mM phenyl-
methylsulfonyl ﬂuoride (PMSF), 1 mM EDTA and 5% glyc-
erol] in a French press at 1500 psi. For immunoblotting, the
washed immunoprecipitates were resuspended in 50 mlo f
2· SDS–PAGE loading buffer and heat denatured at 95C
for 5 min. A total of 10–15 ml of the samples were loaded
on a 10% SDS–PAGE gel or on a 4–12% pre-cast gradient gel
(NOVEX). The separated proteins were transferred on to
Hybond-C extra membrane (Amersham Pharmacia Biotech)
by electroblotting. The membranes carrying the transferred
proteins were blocked with 5% non-fat milk powder and
0.3% Tween-20 in PBS, or with 3% BSA and 0.3% Tween-
20 in PBS, for His-tagged proteins. The membranes were
incubated with primary antibody for 1 h at room temperature,
washed with blocking buffer and incubated with the appropri-
ate secondary antibody. The primary antibodies were used at
the following dilutions: anti-TetraHis (Qiagen) (1:5000), rab-
bitanti-SNEV-867and-866(1:1000),mousemonoclonalanti-
SNEV (1:2000), anti-CDC5L (1:1000). After washing the
blots in blocking buffer 3–4 times (5 min per wash at room
temperature), the membranes were incubated with a secondary
antibody coupled to horseradish peroxidase (HRP). Protein
bands were detected by developing blots using the ECL or
ECL-plus kit (Amersham Pharmacia Biotech).
Yeast two-hybrid assays
Screening for SNEV interacting proteins was performed using
the MATCHMAKER GAL4 Two-Hybrid System3 (Clontech
Laboratories,Palo Alto, USA)according tothe manufacturer’s
guidelines. The plasmids were introduced into S.cerevisiae
strain AH109 (Clontech Laboratories, Palo Alto, USA) by
LiAc-cotransformation. As prey library we used the Match-
maker Aorta cDNA library (Clontech Laboratories, Palo Alto,
USA). We selected interaction-positive clones by growth on
high stringency synthetic drop out medium (4· SD: -Trp/
-Leu/-His/-Ade). Plasmids were prepared from yeast as
described and sequence analyzed.
GST pull-down assay
The pGEX-6P-1 plasmid containing the GST–SNEV cDNA
was transformed into E.Coli BL21. The fusion protein was
expressed using Overnight Express Autoinduction System 1
(Novagen, Darmstadt, Germany) and puriﬁed using the Micro
Spin GST Puriﬁcation Module (Amersham Biosciences,
Uppsala, Sweden) according to the manufacturer’s protocol.
His6–SNEV was expressed in Sf9 insect cells, and afﬁnity
puriﬁed on a Ni
2+-NTA column as described (37). For the
pull-down assay, equal amounts of the puriﬁed proteins (0.5
mg) were mixed together and incubated for 2 h at 4C in CoIP-
buffer [200 mM NaCl, 25 mM Tris–HCl (pH 7.4) and 0.5%
Triton]. Glutathione sepharose 4B beads (Amersham Bio-
sciences, Uppsala, Sweden), equilibrated with CoIP-buffer,
were added and followed by incubation for 2 h at 4C. The
beads were washed 3 times with CoIP-buffer, and proteins
were eluted with SDS–PAGE sample buffer. After SDS–
PAGE, co-precipitated SNEV was detected using anti-4His
antibody (Qiagen, Hilden, Germany). GST was probed
using a goat anti-GST antibody (Amersham, Uppsala, Swe-
den) and an anti-goat peroxidase conjugate used as secondary
antibody (Sigma-Aldrich, St. Louis, USA) for ECL detection.
For competition assays we added synthetic peptides to 0.5 mg
GST–SNEV and again used Glutathione sepharose 4B beads
(Amersham Biosciences, Uppsala, Sweden), equilibrated with
CoIP-buffer, to pull-down GST–SNEV. After 3 washes with
CoIP-buffer, proteins were eluted with SDS–PAGE sample
buffer, and detected by western blotting.
Cell culture and transfection
HeLa cells were grown in DMEM supplemented with 10%
fetal calf serum (FCS) and 100 U/ml penicillin and strepto-
mycin (Life Technologies, Inc.). For immunoﬂuorescence
assays, cells were grown on coverslips and transfected
using Effectene transfection reagent (Qiagen) according to
the manufacturer’s instructions.
Cell staining and immunofluorescence analyses
Cells were washed in PBS and ﬁxed for 5 min in 3.7% (w/v)
para-formaldehyde in CSK buffer [10 mM PIPES (pH 6.8),
10 mM NaCl, 300 mM sucrose, 3 mM MgCl2 and 2 mM
EDTA] at room temperature (RT). Permeabilization was per-
formed with 1% Triton X-100 in PBS for 15 min at RT. Cells
were incubated with primary antibodies diluted in PBS with
1% goat serum for 35 min to 1 h at RT, washed 3 times for
10 min with PBS, incubated for 35 min to 1 h at RT with the
appropriate secondary antibodies diluted in PBS with 1% goat
serum, and washed 3 times for 10 min with PBS. Antibodies
used were Y12 monoclonal antibody (anti-Sm) (dilution
Nucleic Acids Research, 2005, Vol. 33, No. 21 68711:500), rabbit anti-CDC5L (1:500) and rabbit anti-
SNEV-867 (1:100).
Microscopy and image analysis was carried out using a
Zeiss DeltaVision Restoration microscope as described
previously (39).
FRET
SNEV and SNEVD98 inserted in pECFP-C1 and pEYFP-C1,
respectively were transiently co-transfected into HeLa cells by
effectene reagent (Qiagen) according to the manufacturer’s
guidelines. After 24 h FRET images from living cells were
generated by the MicroFRET method according to Youvan
(40). Photos were captured on a Nikon Diaphot TMD micro-
scope with a cooled charge coupled device camera (Kappa
GmbH, Gleichen, Germany), with the YFP, CFP and FRET
ﬁlter sets (Omega Optical Inc., Brattleboro, USA), under
identical conditions and processed with Scion Image software
version beta 4.0.2 (Scion Corp., Frederick, USA). The images
were aligned by pixel shifting, inverted and background was
subtracted. Images from the YFP and CFP ﬁlter sets were
multiplied with their previously assessed correction factors
(0.19 for YFP and 0.59 for CFP) and subtracted from the
FRET ﬁlter set picture. The remaining signal was multiplied
for better visualization and represents the corrected FRET.
In vitro splicing assay and native gels
Nuclear extracts used in the splicing assays were obtained
commercially from Computer Cell Culture Center (Mons,
Belgium). Splicing assays were done using uniformlylabelled,
capped pre-mRNAs incubated with nuclear extract as
described previously (41). Recombinant proteins were
added to the splicing reactions. The adeno-pre-mRNA was
transcribed from Sau3AI-digested plasmid pBSAd1 (42).
The splicing reactions were loaded on a 10% polyacrylamide,
8 M urea denaturing gel and run in 1· TBE to separate the
splicing products. When samples were to be used for the
analysis of splicing complexes, the reactions were loaded
on to a polyacrylamide-agarose composite gel (43) and run
for about 5 h at 25 mA.
RESULTS
SNEV shows sequence homology and similar domain
architecture to the yeast splicing factor Prp19p
After identifying SNEV as differentially expressed between
early passage and senescent cells (1), we were interested in
determining the possible functions of this protein. In order to
detect putative functional motifs of SNEV sensitive sequence
analysis methods were applied and resulted in the detection of
the followingsequencesegments(Figure1A):aU-boxdomain
hit from the SMART (1–68, E-value < 10
28; possible role in
E2 dependent ubiquitination processes), a moderately polar
low complexity region (91–101), a putative coiled coil seg-
ment (114–135), a highly charged region (10 positive, 6 nega-
tive out of 34 amino acid from 175–208), and a large Gb-like
domaincontaining7WD40repeats inaccordance withPFAM,
SMART and REP hits (210–504, E-values between 10
12 and
10
1). Yet another, possibly globular domain (136–174) did
not show any consensus to functional domains.
Sequence database searches reveal close full-length
sequential homologues in Rattus norvegicus (BAA95215),
Drosophila melanogaster (AAD46846), Caenorhabditis
elegans (Q10051), Arabidopsis thaliana (two different hits
AAB80652 and AAB70423), Plasmodium falciparum
(T18432), Saccharomyces pombe (O14011) and also to
S.cerevisiae (Prp19p). Although sequence similarity is very
high only in the N-terminal region (Figure 1B), the domain
architecture of SNEV and Prp19p is similar throughout the
whole protein sequence (Figure1A).
Prp19p is an essential protein for S.cerevisiae, and has
already been shown in several studies to play an important
role in splicing and DNA repair. Therefore, we tried to com-
plement a yeast Prp19p mutant strain with human SNEV or
with different human–yeast chimeric constructs.
A SNEV/Prp19p chimeric protein restores
wild-type phenotype in a temperature
sensitive Prp19p mutant strain
The Prp19p mutant yeast strain MG5128 (pso4-1) was trans-
formed with plasmid constructs containing various wild-type
and chimeric proteins in order to test restoration of the wild-
type phenotype regarding temperature sensitivity, UV resis-
tance, forward mutability and sporulation. The summarized
results are shown in Figure 2A. Positive transformants were
selected by the nutritional marker URA at the permissive
temperature of 30C and analyzed for expression of the
His6-tagged proteins by western blotting, which was con-
ﬁrmed for all transformants (Figure 2B). By incubation of
the transformed yeast strains at 37C the potential of the
recombinant SNEV chimera to complement temperature sen-
sitivity was assessed (Figure 2C). Empty vector control did not
result in growth of MG5128 at the restrictive temperature,
while yeast overexpressing wild-type Prp19p including a
C-terminal His6-tag were able to divide at 37C, indicating
that the C-terminal His6-tagged protein is functional. Overex-
pression of the pso4-1 derived Prp19p mutant protein that
carries a point mutation leading to substitution of the highly
conserved leucine at position 45 by serine (L45S) comple-
mented the temperature sensitivity as well. No other mutation
in the promoter or terminator sequence was observed (data not
shown).
Prp19 without the U-box (Prp19[68–503], construct f in
Figure2A)aswellasSNEV[1–66]Prp19[68–503](constructe)
were able to complement the defects of MG5128, indicating
that the U-box is not necessary for complementation in the
background of the MG5128 mutant strain.
Furthermore, the human–yeast chimeric protein SNEV
[1– 91]Prp19[98–503] (construct g) restores wild-type pheno-
type in contrast to its control, the N-terminal deletion of
97 amino acids, Prp19[98–503] (construct h), indicating
that the amino acids from position 68 to 97 are of major
importance for the function of SNEV and Prp19p.
None of the other chimeric constructs (i–l) was able to
complement MG5128, however, wild-type SNEV negatively
affected yeast growth suggesting that competition with the
yeast protein occurs (data not shown).
The same constructs that were effective for enabling growth
at the restrictive temperature restored the wild-type behaviour
when we tested the ability to sporulate on KAC agar plates
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resistance to UV radiation (Figure 2E). All results and
constructs are summarized in Figure 2A. These data suggest
that SNEV might have the same cellular function as Prp19p,
however, further analysis of SNEV’s role during the splicing
process was necessary for conclusive interpretation.
SNEV colocalizes with splicing factors in
HeLa cell nuclei
Since SNEV appears to be related to Prp19p both at the struc-
tural and functional level, we decided to investigate if
the protein has a role in human pre-mRNA splicing. We
tested in indirect immunoﬂuorescence experiments whether
endogenous SNEV associates with known human splicing
factors in the cell nucleus and localizes to nuclear structures
called ‘speckles’, where several other pre-mRNA splicing fac-
tors accumulate. We transiently expressed a ﬂuorescently
tagged SNEV fusion protein in HeLa cells and stained with
anti-SNEV antibodies to check if the tagged protein accumu-
lates in the same nuclear structures as endogenous SNEV
(Figure 3A). We next investigated SNEV’s association with
other splicing factors in HeLa cell nuclei. The results from
these experiments indicate that the protein colocalizes within
Construct  Sporulation [%]  SD  Cells counted 
empty vector  0.00 0.00 2743 
wt Prp19  30.04 8.81 2646 
SNEV  0.00 0.00 2571 
SNEV[1-66]Prp19[68-503]  7.82 0.92 2965 
Prp19[68-503]  9.14 3.81 5752 
SNEV[1-91]Prp19[98-503]  12.44 6.88 4941 
Prp19[97-503]  0.00 0.00 3166 
SNEV[1-205]Prp19[208-503]  0.00 0.00 1538 
Prp19[208-503]  0.00 0.00 1529 
SNEV[1-420]Prp19[401-503]  0.00 0.00 2528 
Prp19[401-503]  0.00 0.00 2090 
pso4-1  27.44 3.24 3960 
D
E
Figure 2. Human–yeast chimeric SNEV complements the mutant phenotype of MG5128. (A) Overview of SNEV and Prp19 constructs tested in this study. Length
indicates the number of amino acids (aa), MW is the molecular weight (kd), (+) indicates ability to grow at the indicated temperature, to sporulate or to perform
forwardmutability.()nogrowth,(n.d.)notdetermined.Thestarinconstructdindicatesthepointmutation.(B)Allchimericconstructsintroducedintothemutant
yeast strain are translated into protein. Western blots after SDS–PAGE of cell-lysates of MG5128 transformed with pYPGE15, containing various chimeric
constructs, which were fused to a His6-tag. Detection was performed using anti-TetraHis mouse antibody as primary and peroxidase-conjugated goat-anti-mouse
antibodyassecondaryantibody.Calculatedmolecularmasses[kDa]areindicated.Thesmallbandsinlanes4–6and11–14representdegradationproductsresulting
from the lysis process. (C) Growth at the permissive (30C) and the non-permissive (37C) temperature of MG5128, transformed with the various constructs was
analysed. All clones showed growth at 30C, whereas at 37C only transformants containing wtPrp19p, SNEV[1–66]Prp19p[68–503], Prp19p[68–503] or SNEV
[1–91]Prp19p[98–503] were able to form colonies. Sector 1: wt Prp19p (positive control), 2: empty vector control, 3: SNEV, 4: SNEV[1–66]Prp19p[68–503],
5: Prp19p[68–503], 6: SNEV[1–91]Prp19p[98–503], 7: Prp19p[97–503], 8: SNEV[1–205]Prp19p[208–503]. (D) Ability of the various constructs to sporulate on
KAC agar plates. MG5128 transformed with the various constructs was incubated at 30C for one week, vegetative and sporulated cells were counted. Sporulation
wascalculatedastheratioofsporulatedversusvegetativecells.Meanandstandarddeviation(SD)werecalculatedfromatleastthreeindependentexperiments.The
totalnumberofcellscountedisindicated.(E)Thehuman–yeastchimericproteinSNEV[1–66]Prp19[68–503]restoreswild-typephenotyperegardingUVsensitivity
and forward mutability. Survival of the various MG5128 transformants after UV-irradiation (left panel) (266 nm) and ability of the various chimeric constructs to
restore wild-type like forward mutability by growth on canavanine containing media after UV-irradiation (right panel). Number of mutants has been calculated as
mutants per UV radiation surviving cells.
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proteins as detected by the Y12 antibody (Figure 3B) and
CDC5L (44) (Figure 3C). Colocalization in nuclear speckles
is observed in all cases.
SNEV is an essential human splicing factor
Since SNEV associates with other splicing factors in cells,
we tested if the presence of SNEV in nuclear extracts is
essential for the splicing reaction. Therefore, we performed
immunodepletion experiments. Since it has been shown pre-
viously that SNEV is part of the CDC5L associated complex
(19),we used high salt concentrations in the nuclear extracts to
disrupt this complex before depletion. After removing the
NaCl by dialysis, the extracts were tested for splicing efﬁci-
ency. The SNEV immunodepleted nuclear extracts showed a
reduction in splicing activity. No reduction of splicing efﬁci-
ency was observed when various control antibodies were used
in immunodepletion experiments (Figure 4A). Since add back
ofcytoplasmic extract S100, thatalso containsSNEV (datanot
shown) restores the splicing efﬁciency, we were able to
exclude the possibility that unspeciﬁc inhibition due to sample
processing had occurred. Addition of recombinantly expressed
SNEVinincreasingamounts,however,didnotrestoresplicing
activity; on the contrary, complete inhibition of the reaction
was observed. The success of SNEV immunodepletion was
monitored by western blotting. Indeed, nuclear extracts con-
tained signiﬁcantly less SNEV after depletion, when compared
to the controls that were treated with IgG and a-HCF anti-
bodies. However, when we tested, if 1 M NaCl was sufﬁcient
to disrupt the CDC5L complex, we probed the immunopre-
cipitates also positive for the presence of CDC5L. This co-
depletion of CDC5L together with SNEV from the nuclear
extracts indicates a very high stability of the CDC5L associ-
ated complex. Thus, it is comprehensible that add back of
recombinant SNEV isnot sufﬁcientto restoresplicing activity.
But why do we see complete inhibition of splicing by recom-
binant SNEV?
The inhibition of the splicing reaction seems to take place at
the step of spliceosome assembly, since we observed that
addition of increasing amounts of recombinant SNEV to
SNEV-depleted as well as untreated nuclear extracts leads
to inhibition of spliceosome formation as seen on native
gels, while no block in spliceosome assembly is seen when
equimolar amounts of another His-tagged protein is added
(Figure 5A). This is not due to decreased stability of the
spliceosome by heparin (data not shown). Additionally, we
observed that already formed spliceosomes are not disrupted
upon addition of SNEV at different time points (from 0 to
50 min) during the reaction, indicating that assembled spliceo-
somesare protectedagainstthe disruptive activity(Figure 5B).
These data again argue in favour of a role of SNEV in the
splicing reaction, however, proof of a direct role of SNEV
escaped due to the high stability of the CDC5L complex.
SNEV forms homo-oligomers
Additional help in clarifying the role of SNEV came from our
project that aims at the identiﬁcation of SNEV interacting
proteins using yeast two-hybrid screening. Thereby, we iden-
tiﬁed several potential SNEV interacting proteins as well as
SNEV itself. Figure 6A shows colony formation of yeast after
co-transformation with SNEV as bait and prey protein. In
order to map the interaction site we co-transformed various
truncated SNEV mutants together with full length SNEV.
Only mutants containing the amino acids 68–90 gave rise
to colonies on high stringency medium. Furthermore, we
were able to show that a minimal region containing amino
acid 56 to92 (Mut 1)or 56 to 121 (Mut 4) isnotonly necessary
but also sufﬁcient to mediate SNEV self interaction, while
Figure 3. SNEVassociatesinvivowithSmproteinsaswellaswiththesplicing
factor CDC5L, and fusion of SNEV to EGFP does not alter the cellular loca-
lization of SNEV. HeLa cells were grown, transfected with an EGFP–SNEV
fusion construct, fixed and stained by indirect immunofluorescence. The
images shownin the panels are representative optical sectionsfrom the respec-
tive deconvolved datasets. (A) GFP–SNEVexpressingHeLacells stainedwith
anti-SNEV antibody 867. Red represents SNEV indirect staining, and green
indicatesEGFP–SNEVexpression.(B)Cellswerestainedwiththetheanti-Sm
protein monoclonal antibody Y12 (57). Red indicates Y12 staining as above,
while green represents EGFP–SNEV expression. (C) Cells stained with anti-
CDC5L antibodies. Red represents anti-CDC5L staining, while green shows
EGFP–SNEV expression. In all the panels, yellow indicates co-localization of
thetwoproteins.Notethattheuseofthefluorescentlylabelledproteinresultsin
astrongersignalfromthefusionprotein.Thisshowsupasasmallfractionofthe
label that does not co-localize.
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colony formation on 4· drop out medium (Figure 6C). This
would suggest that the binding site lies between amino
acid positions 56 and 66, however, it cannot be excluded
that these 10 amino acids are only necessary for correct
formation of an interaction site lying within the amino
acids from 66 to 92.
As an independent method conﬁrming direct SNEV–SNEV
interaction invitro,we performedGSTpull-downassays using
recombinant His-tagged and GST-tagged SNEV (Figure 6D).
GST–SNEV was recombinantly expressed in E.coli, while
His-tagged SNEV was derived from insect cells and afﬁnity
puriﬁed on Ni-NTA agarose beads (37). Neither the beads nor
GST alone precipitated the His-tagged SNEV, but it was efﬁ-
ciently pulled down by GST–SNEV. These results suggest that
SNEV-fusion proteins interact directly in vitro (Figure 6D).
When we tested the synthesized peptide Prp19-1 spanning the
region from 56 to 74 as competitor for SNEV–SNEV inter-
action in the GST pull-down experiment, the amount detected
by western blots decreased signiﬁcantly, while the control
peptide Prp19-scr consisting of the scrambled sequence did
notreduce the precipitated amount ofGST-SNEV (Figure 6E).
The reduction of precipitated SNEV decreases also in a dose
dependent manner (Figure 6F). This indicates that the peptide
efﬁciently competes with SNEV self interaction.
An additional indication that SNEV interacts with itself
derives from FRET experiments. By using ECFP and EYFP
tagged SNEV we observed signiﬁcant FRET signals, while the
negative control using EYFP-SNEV and ECFP–SNEVD98
lacking the interaction site did not produce any signiﬁcant
FRET signals (Figure 6G). Although the FRET experiment
does not allow localizing the interaction within the cell, these
results still indicate that SNEV–SNEV self interactions may
exist in HeLa cells in vivo.
Synthetic peptides containing sequences in the
self-interaction domain inhibit pre-mRNA splicing
Since the region from 56 to 94 was sufﬁcient to bind SNEV in
the Y2H system and to compete with the SNEV–SNEV inter-
action in GST pull-down experiments, we decided to investi-
gate whether peptides containing sequences in this self-
interaction domain of SNEV will compete with the endoge-
nous protein for binding and thus interfere with SNEV’s
function in splicing. We therefore used peptides containing
the following sequences present in the self-interaction
A
B
Figure 4. Depletion of SNEV decreases the splicing efficiency of nuclear
extracts. (A) After immunodepletion of SNEV from nuclear extracts (NE)
treated with 1 M NaCl in order to disrupt the CDC5L complex the extracts
were tested for splicing efficiency. Lane 1 shows the unspliced adenoviral pre-
mRNA.Adecreaseofthesecondcatalyticalstepofthereactionwasobservedin
the SNEV depleted extracts when compared to depleted controls, where irre-
levantantibodieswereusedfordepletion(lanes3and4)orwhereuntreatedNE
wasusedforinvitrosplicing(lane2).Splicingefficiencyisrestored,whenS100
cytoplasmicextractenrichedforsplicingfactorsisaddedtotheSNEVdepleted
NE(lane10).However,addbackofincreasingamountsofrecombinant SNEV
results in concentration dependent inhibition of the first step of the reaction
(lanes 6–9). (B) The antibody used to immunodeplete the high salt nuclear
extracts recognizes a distinct band at the expected molecular weight of 56 kDa
in nuclear extract (lane NE). While neither IgG nor an irrelevant antibody
directed against HCF reduce the amount of SNEV in the nuclear extracts used
in the splicing assay after immunodepletion, a marked decrease in SNEV was
observed after depletion with a-SNEV antibody. This is consistent with the
larger amounts that are eluted from the a-SNEV antibody coupled beads.
Although 1 M NaCl was used to disrupt the CDC5L associated complex,
CDC5L was co-precipitated together with SNEV. Supernatant: Nuclear ex-
tracts after immunodepletion. Beads: Precipitates eluted from the beads. NE
(nuclear extract), Igg: IgG coupled beads, HCF: a-HCF antibody coupled
beads, DD: a-SNEV antibody coupled beads.
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2: (75-LKALQDEWDAVMLHSFTL-92), Prp19-3: (66-
PSATSIPAILKALQDEWDA-84) and Prp19-4: (56-KVAH-
PIRPKPPSATSIPAILKALQDEWDAVMLHSFTL-92). As a
control we used Prp19-scr, a scrambled version of Prp19-1
(N-KSIAATSPIPVRKIHPAP-C). Upon addition of these pep-
tides, we observed that splicing can be inhibited when either
Prp19-1 or PRP19-4 is added to the splicing reaction whereas
the peptides Prp19-2 and -3 did not block splicing (Figure 7A).
In order to deﬁne the potency of Prp19-1 and Prp19-4 we used
increasing amounts of these peptides in comparison to the
scrambled version of Prp19-1 as negative control. While
Prp19-1 inhibited the splicing reaction completely at about
14 nmol, about 21 nmol of Prp19-4 were needed to show
the same effect. Neither concentration of the scrambled pep-
tide showed a decrease in splicing efﬁciency (Figure 7B).
These results indicate that the SNEV sequences represented
by the inhibitory peptides are essential for the proteins func-
tion in splicing.
Inhibition of splicing by Prp19-1 peptide is due to a
decrease in spliceosome stability
In order to ﬁnd out whether the splicing inhibition observed
above is due to a speciﬁc inhibition of splicing catalysis or
spliceosome assembly, we next investigated the effect of the
peptides on spliceosome assembly. Splicing reactions were
prepared as above except that the reactions were loaded on
to a native gel at the end of the reaction in order to separate the
splicing complexes. The results obtained from these experi-
ments indicate that the inhibitory peptide Prp19-1 prevents
formation of splicing complexes whereas the control peptide
does not block assembly of the spliceosome (Figure 7C). It is
of note that the larger peptide Prp19-4 that blocks catalysis at
higher concentrations does not block spliceosome formation.
It is possible that Prp19-1 has higher afﬁnity to SNEV than the
larger Prp19-4 peptide. However, it is also possible that SNEV
interaction is inside of the complex and only the smaller
Prp19-1 is able to disrupt the SNEV self interaction, while
the larger peptide is sterically blocked from the interaction
site. More experiments are needed to address the differences
between the effects of the peptides.
However, addition of Prp19-1 at different time points, start-
ing with a pre-incubation of nuclear extracts for 10 min up to
addition just before loading of the gel, showed, that already
formed complexes are disrupted by Prp19-1, while Prp19-scr
as negative control has no effect. These results suggest that
SNEV–SNEV self interaction may be needed for the efﬁcient
formation and stability of splicing complexes. Although most
members of the Prp19 associated complex have been found to
enter the spliceosome just before catalysis, SNEV has been
observed to be already present in the A complex (45).
Additionally these results might help to explain the cause of
the inhibitory effect of adding recombinant SNEV to splicing
reactions. Although this recombinant SNEV was active in
ubiquitination assays (data not shown), the recombinant pro-
tein might not be active as a splicing factor and thus might
compete with the binding sites in endogenous SNEV similarly
to the inhibitory peptide.
DISCUSSION
By a subtractive hybridization method various differenti-
ally expressed genes were identiﬁed from early passage and
senescent HUVECs (1). One of these genes, the unknown
gene 4, now termed SNEV, was selected for further
characterization.
A
B
Figure 5. SNEV inhibits spliceosome formation, but does not disrupt already
formed complexes. (A) Formation of the splicing complexes was observed by
separation on native gels. Lane 1: nuclear extract (NE) on ice as negative
control, lane 2: nuclear extract, lane 3: NE after treating with pre-immune
IgG coupled beads, lane 4: NE after SNEV depletion, lane 5: NE after treating
with anti-SNEV coupled beads pre-incubated with recombinant His6–SNEV,
lane 6: NE after addition of recombinant His6-SNEV, lane 7: NE after addition
of the same amount of recombinant His6-VP16 proteins as control. Immuno-
depletionofSNEVonlyslightlydecreasesformationofthespliceosome,while
after addition of recombinant SNEV no splicing complexes can be detected.
(B)AlreadyformedcomplexesarenotdisruptedbyadditionofSNEVinatime
courseexperiment.Lane1:NEonice,lane2:NE,lane3:NEwithSNEVadded
before starting the reaction, lane 4: SNEV was added 10 min after starting of
the reaction, lane 5: 20 min; lane 6: 30 min, lane 7: 40 min, lane 8: 50 min after
starting the reaction.
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domain architecture that is highly similar to the one found
for the yeast Prp19p protein (46). The C-terminal portion of
SNEV contains 7 WD40 repeats that are similar to Gb-like
proteins. WD40 repeats have a typical length of about
40 residues, form a b-propeller structure, and are proposed
to mediate protein–protein interactions (47). WD40 motifs
are also a common motif in F-box proteins and E3 ligase
D
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G
6878 Nucleic Acids Research, 2005, Vol. 33, No. 21complexes (48). The putative SNEV coiled coil region
represents another segment with protein–protein interaction
ability (49).
Within the ﬁrst 68 amino acids a U-box (a modiﬁed RING
ﬁnger) domain was found by SMART search. This conserved
domain is found in a large variety of proteins (50) and possibly
mediates the interaction of the U-box protein with ubiquitin
conjugated proteins thus activating their further multi-
ubiquitination by acting as E4 ubiquitin ligase enzymes
(51). In vitro assays by Hatakeyama and coworkers (17)
have shown that SNEV possesses an E3 ubiquitin ligase activ-
itywhentestedwithUbc3(cdc34) actingasanE2enzyme, and
the ubiquitination has been suggested to be dependent on the
U-box. Additionally, SNEV mediates multi-ubiquitination via
the K48 residue, which is known to be the proteasome target-
ing signal (52,53). Recently we observed that SNEV also
interacts with the proteasome, suggesting that it ‘escorts’ its
substrate to the site of destruction (18).
Since the putative yeast homologue of SNEV, Prp19p, has
been well characterized, but shows only limited sequence
homology (23%) we next tested if SNEV or SNEV–Prp19
chimeric proteins are able to complement the pleiotropic
defects of the yeast mutant strain pso4-1. This mutant strain,
MG5128, shows a highly interesting phenotype including tem-
perature sensitivity, blocked sporulation and impaired muta-
bility (10) as well as an accumulation of pre-mRNA at the
restrictive temperature (14).
Here we have shown that a chimeric protein containing the
human U-box and adjacent 30 amino acids (SNEV[1–
91]Prp19p[98–503]) restores the wild-type phenotype, in con-
trast to its control, where only the Prp19p part (Prp19p[98–
503]) was introduced. Since the chimeric protein consisting of
the 205 human N-terminal amino acids fused to the Prp19p
WD40 repeat domain (construct i) was not effective, at least
91, but not more than 204 human N-terminal amino acids, will
restore the wild-type yeast phenotype.
Equally effective in restoring wild-type properties of pso4-1
was the truncated Prp19p lacking the U-box (Prp19[68–503])
that we had designed as a control. This result is surprising in
several regards: (i) the mutation of MG5128 was found within
the U-box itself at the highly conserved leucine at position
45 (50), and no other mutation neither in the promoter nor
the terminator sequence was observed (data not shown),
(ii) overexpression of the mutant protein results in complete
restoration of the defects of MG1528 (construct d), (iii) the
U-box is essential for viability in Prp19p null yeast (46).
Therefore we suggest that the mutation of L45 results in a
destabilization of the Prp19p structure not only in the U-box,
but also in the adjacent regions.
Expression of human SNEV in the mutant yeast strain
resulted in diminished growth rates even at the permissive
temperature of 30C, indicating that it competes with
Prp19p most probably by its N-terminus, since the human
C-terminal part cannot substitute for the function of the C-
terminal part of Prp19p. This is consistent with our result that
constructs carrying parts of the human WD40 domain cannot
complement the yeast mutant.
Taken together, the results of the yeast complementation
experiments suggest that at least the N-terminal part of SNEV
can complement Prp19p function and therefore SNEV might
be its functional orthologue. Prp19p is a known yeast splicing
factor, therefore if SNEV is a functional homologue of the
yeast protein, it should function in pre-mRNA splicing in
human cells. Immunostaining and cDNA cell transfection
experiments show that SNEV colocalizes with well known
splicing factors like Sm proteins and CDC5L in HeLa cell
nuclei. These results suggest that SNEV may function in splic-
ing and conﬁrm previous observations that indicate an asso-
ciation of SNEV with the human CDC5L associated splicing
factor complex (19).
We next investigated the potential for a direct role of
SNEV in human pre-mRNA splicing by immunodepleting
the protein from HeLa nuclear extracts. The results from
these experiments indicate that removing SNEV from nuclear
extracts prevents the formation of splicing products. Even
though we performed the depletion from nuclear extracts
treated with high salt concentrations, we still co-depleted
CDC5L. Although these results conﬁrm the importance of
the CDC5L associated complex for in vitro splicing reactions,
the question still remained, whether or not SNEV alone is
an essential splicing factor in human cells.
A result from a different line of experiments helped us to
address this question. By using yeast two-hybrid screenings
to identify SNEV interacting proteins, we observed that the
protein interacts with itself. The interaction was conﬁrmed
using GST pull-down assays as well as by FRET experiments
and subsequently, the interaction site was narrowed down
to 30 amino acids. Synthetic peptides covering these amino
Figure 6. SNEV forms homo-oligomeres that are dependent on the amino acids 56–92 of SNEV. (A) SNEV interacts with SNEV in a yeast two-hybrid assay when
GAL4-AD-SNEV and GAL4-BD-SNEV are co-transformed into the yeast reporter strain AH109 (AD-SNEV + BD-SNEV). Neither co-transformation of SNEV
fusion to the GAL4 activating domain (AD-SNEV + BD) nor to the DNA-binding domain (BD-SNEV + AD) together with the respective empty second plasmid
allowedformationofyeastcoloniesonhighstringencydrop-outmediaplates.(B)DomainmappingoftheselfinteractingaminoacidswasperformedusingtheYeast
two-hybrid system. Various truncated SNEV constructs were used as prey. Growth of double transformants on high stringency media plates was observed only for
variants containing amino acids 68–90, which we therefore termed self interaction domain (SID). (C) In order to confirm that the SID is sufficient for homo-
oligomerization,foursmalloverlappingpeptideswereclonedandtestedbyY2H.Co-transformationwithSNEVresultedingrowthofyeastdoubletransformantson
highstringencymediaplatesonlywiththeregion56–92and56–121(red),whileneither66–103nor76–121(green)allowedyeastcolonyformation.U-box:domain
necessaryforubiquitinE3ligaseactivityofSNEV;SID:SelfInteractiondomain;LCR:lowcomplexityregion;GL2:globulardomain2,WD40:domaincontaining
7 WD40 repeats; numbers indicate the amino acid positions, ‘+’ indicates colony formation on high stringency drop out media, ‘’ indicates no colony formation.
(D) The SNEV self-interaction was confirmed by GST pull-down experiments using affinity purified His6–SNEV and GST–SNEV. While no His6–SNEV was
detectable in the controls using either GST or beads alone (lanes 2 and 3), GST–SNEV results in co-precipitation of His6–SNEV (lanes 4 and 5). (E) Addition of
Prp19-1 peptide to GST–SNEV reduces the amount of precipitated SNEV (Prp19-1), whereas addition of the scrambled control peptide (Prp19-scr) does not. This
amount is comparable to the one without addition of peptides (GST–SNEV) as well as to the amount of GST–SNEV added to the beads (Input). (F) Increasing
amountsofthePrp19-1peptide(0,5and10nM)decreasetheamountofprecipitatedGST–SNEV(G)AdditionalconfirmationofSNEVselfinteractionderivesfrom
FRET analysis. Upper panel: Co-transfection of ECFP–SNEV and EYFP–SNEV into HeLa cells resulted. Pictures were taken using CFP-filter (ECFP–SNEV)
displayed in cyan, YFP-filter (EYFP–SNEV). FRET represents the calculated net FRET signal. Lower panel: negative control using ECFP–SNEVD98 lacking the
interaction domain.
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Figure 7. A peptide that spans the SNEV self interaction site inhibits the splicing reaction by interfering with spliceosome stability. (A) Overlapping peptides that
span the self interaction site of SNEV were synthesized and added to standard splicing reactions. While nuclear extract (NE) as positive control shows efficient
splicingofanadenoviralpre-mRNA,thepeptidesPrp19-1andPrp19-4showinhibitionofthesplicingreaction,whilePrp19-2andPrp19-3donotaffectformationof
lariat and of joined exons.(B) Increasing amounts(7, 14 and 21 nmol) of the two effective peptides were added to the splicing reaction, showing higherpotency for
Prp19-1 than for Prp19-4. As negative control the same amounts of Prp19-scr, the scrambled version of Prp19-1 was used. (C) Splicing complexes have been
separatedonanativegel.AdditionofPrp19-1(NE + Prp19-1)peptideresultsininhibitionofformationofC,BandAsplicingcomplexessimilartoincubationofthe
splicing reaction on ice (NE on ice), while Prp19-4 (NE + Prp19-4) as well as Prp19-scr (NE + Prp19-scr) similar to the positive control (NE) do not
show any reduction in spliceosome assembly. (D) 21 nmol Prp19-1 were added to splicing reactions at different time points: either pre-incubation for 10 min
(10min),atthestart ofthereaction(0min),orat 10min,25minand50minafter startingthesplicingreaction.After55minall reactionswereloadedon tonative
gels. Neither A, B nor C complexes can be detected independent from the time point of peptide addition, while the scrambled peptide does not interfere with
spliceosome formation.
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the SNEV–SNEV interaction. Indeed, less SNEV was ‘pulled
down’ in the presence of increasing amounts of Prp19-1
peptide, indicating that the SNEV–SNEV interaction is inhib-
ited by the peptide in vitro.
Addition of these peptides to in vitro splicing experiments
blocks pre-mRNA splicing. Similar results were obtained
previously by targeting the interaction of two other CDC5L
associated proteins CDC5L and PRLG1 by synthetic peptides
(54). While these peptides interfered with splicing catalysis,
addition of the Prp19-1 peptide interfered with spliceosome
assembly. This ﬁnding is supported by the observation
that SNEV joins the human spliceosome as early as at the
pre-spliceosome stage (45), indicating that a role of SNEV
in early spliceosome assembly is possible. Although we
cannot rule out entirely that Prp19-1 has effects on other
splicing factors as well, the competitive GST pull-down
assay strongly supports a speciﬁc function on endogenous
SNEV. We further suggest that SNEV might act as a scaf-
fold on which the other splicing factors assemble, covering
SNEV at the inside of this complex. This would be in keep-
ing with the ﬁnding that recombinant SNEV prevents
spliceosome assembly but does not disrupt the already
formed complexes, while the small Prp19-1 peptide is able
to disrupt also the fully assembled spliceosomes. Prp19-4,
while still efﬁciently inhibiting the splicing reaction at higher
concentrations, might have lower afﬁnity or sterical dis-
advantage and might therefore not be able to prevent
spliceosome assembly or disrupt already formed spliceo-
somes. However, further experiments are necessary to explain
the observed differences in the capacity to disrupt the
spliceosome.
While addition of recombinant SNEV in excess inhibits
splicing in vitro, 2- to 3-fold overexpression extends the
life span of endothelial cells (2). This seemingly contradictory
result might be explained that recombinant SNEV is not cor-
rectly folded and therefore competing with the endogenous
SNEV in nuclear splicing extracts, or by the excess added
in vitro that might titrate other necessary factors, while stable
SNEV overexpressing cells generate fully functional SNEV,
that besides its function as splicing factor has also DNA pro-
tective functions (55) and increases stress resistance of
endothelial cells (2).
Consistent with our results, the self-interaction domain of
yeast Prp19p was also mapped by Ohi and coworkers (56) to
the amino acids from 66 to 141. Disruption of the tetramer-
ization of Prp19p was achieved by mutating the highly con-
served W88 to proline, which was lethal in a Prp19p null
background, while a change to alanine did not interfere
with self interaction or with yeast viability.
Considering that Prp19p and SNEV are orthologues and
show high conservation as well as exchangeability in the
N-terminal region in our complementation experiments,
these results might indicate that although the region 54–74
is sufﬁcient for self interaction, the adjacent amino acids
play a crucial role for accessibility of this region as
shown by the W88P mutation. This might also explain why
the L45S mutation was complemented by Prp19D1–67. The
mutated form might destabilize the Prp19p associated
complex, while it can form properly without the N-terminal
67 amino acids (as shown by our domain mapping). Therefore
the pleiotropic phenotype of the L45S mutation might not
only derive from an altered activity of the U-box, but also
from a decreased complex stability.
In summary, our results together with already published
data suggest that SNEV is the orthologue of Prp19 and has
been highly conserved during evolution. Both proteins show
similar domain architecture despite low sequence simila-
rity at the C-terminal half. They both carry a U-box which
in vitro shows E3 ubiquitin ligase activity (17,46), both pro-
teins interact with the proteasome (18), both have been
reported to play a role in DNA repair (10,55), and both are
subunits of a highly conserved complex (termed NTC in
yeast and CDC5L associated complex in human cells),
which is essential for splicing. It will be very interesting to
understand how these multiple functions are integrated
into cellular pathways and how splicing, DNA repair and
the ubiquitin proteasome pathway are interrelated.
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